Clinical Trial Update: Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II

View source ↗

Summary

Clinical trial update indicates completion of a pediatric ancillary study to STOP II, examining Chlamydia infection, sickle cell disease, and stroke risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chlamydia Infection
• Sickle Cell Disease
• Stroke

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Blood Disease, Anemia, Sickle Cell | Status: COMPLETED